Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: BI 907828
Drug: ezabenlimab
Drug: BI 754111

First Posted Date: 2019-05-28

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 120

Registration Number: NCT03964233

Locations: 🇺🇸
NEXT Oncology-Irving-69444, Irving, Texas, United States
🇺🇸
NEXT Oncology-San Antonio-65273, San Antonio, Texas, United States
🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain

and more 20 locations

A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Drug: Pirfenidone
Other: Untreated Cohort

First Posted Date: 2019-05-21

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13264

Registration Number: NCT03958071

Locations: 🇺🇸
Plymouth Meeting, Plymouth, Pennsylvania, United States

Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Spiolto® Respimat®
Drug: Triple-Therapy (LAMA/LABA/ICS)

First Posted Date: 2019-05-17

Last Posted Date: 2024-04-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 469

Registration Number: NCT03954132

Locations: 🇩🇪
Dr. Graubner, Bad Sachsa, Germany
🇩🇪
Dr. Kopf, Berlin, Germany
🇩🇪
Dres. Bartels/Bartels, Breuberg, Germany

and more 71 locations

Global Atrophie Biomarker Evaluation Study (GABiE)

Terminated

Conditions: Age-related Macular Degeneration

Interventions: Diagnostic Test: Diagnostics

First Posted Date: 2019-05-02

Last Posted Date: 2021-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3

Registration Number: NCT03935126

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇨🇭
University Hospital Basel, Basel, Switzerland

This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306
Drug: Moxifloxacin
Drug: Placebo matching to BI 409306

First Posted Date: 2019-05-01

Last Posted Date: 2024-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 47

Registration Number: NCT03934203

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1467335

First Posted Date: 2019-04-25

Last Posted Date: 2021-06-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT03927209

Locations: 🇬🇧
Northwick Park Hospital, Harrow, United Kingdom

A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1265162 (T1)
Drug: BI 1265162 (T2)
Drug: BI 1265162 (R)
Drug: BI 1265162 (T3)

First Posted Date: 2019-04-08

Last Posted Date: 2022-07-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT03907280

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894
Drug: Placebo

First Posted Date: 2019-04-05

Last Posted Date: 2020-08-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT03904576

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands

A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: Donepezil

First Posted Date: 2019-04-05

Last Posted Date: 2021-02-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT03905096

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894 (D)
Drug: BI 1358894 (B)
Drug: BI 1358894 (E)
Drug: BI 1358894 (C)
Drug: BI 1358894 (A)

First Posted Date: 2019-03-27

Last Posted Date: 2021-11-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT03892616

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy